Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Cyclopharm’s US Revenue More Than Doubles as Technegas Rollout Expands

CYC: $0.385 +4.05% · MC: $58M

Cyclopharm reported record quarterly US revenue, more than double the same period a year earlier and up nearly half from the previous quarter. US revenue for the first nine months exceeded the whole of the previous year, while the installed base of Technegas systems grew by more than four-fifths over six months. Group revenue rose by nearly a seventh over the nine months, and average monthly cash burn roughly halved from the second half of the previous year.

Source announcements: 2026-10-29 10:29 to 2026-10-29 10:29 Sydney time
Story updated 2026-10-29 15:19 Sydney time
SourcesCyclopharm Q3 2026 Update
Comments